These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27322162)

  • 1. Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis.
    Jha S; Ismail N; Clark D; Lewis JJ; Omar S; Dreyer A; Chihota V; Churchyard G; Dowdy DW
    PLoS One; 2016; 11(6):e0157554. PubMed ID: 27322162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert
    Pallas SW; Courey M; Hy C; Killam WP; Warren D; Moore B
    Appl Health Econ Health Policy; 2018 Aug; 16(4):537-548. PubMed ID: 29862440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.
    Diel R; Nienhaus A; Hillemann D; Richter E
    Eur Respir J; 2016 Feb; 47(2):575-87. PubMed ID: 26647440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xpert®MTB/RIF for the Diagnosis of Tuberculosis in a Remote Arctic Setting: Impact on Cost and Time to Treatment Initiation.
    Oxlade O; Sugarman J; Alvarez GG; Pai M; Schwartzman K
    PLoS One; 2016; 11(3):e0150119. PubMed ID: 26990299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
    Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT; Khaliqov A; Zamudio C; Perkins MD; Boehme CC; Cobelens F
    PLoS Med; 2011 Nov; 8(11):e1001120. PubMed ID: 22087078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid culture.
    Balcha TT; Sturegård E; Winqvist N; Skogmar S; Reepalu A; Jemal ZH; Tibesso G; Schön T; Björkman P
    PLoS One; 2014; 9(1):e85478. PubMed ID: 24465572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.
    Andrews JR; Lawn SD; Rusu C; Wood R; Noubary F; Bender MA; Horsburgh CR; Losina E; Freedberg KA; Walensky RP
    AIDS; 2012 May; 26(8):987-95. PubMed ID: 22333751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis.
    Thompson RR; Nalugwa T; Oyuku D; Tucker A; Nantale M; Nakaweesa A; Musinguzi J; Reza TF; Zimmer AJ; Ferguson O; Turyahabwe S; Joloba M; Cattamanchi A; Katamba A; Dowdy DW; Sohn H
    Lancet Glob Health; 2023 Feb; 11(2):e278-e286. PubMed ID: 36669808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey.
    Dorman SE; Chihota VN; Lewis JJ; Shah M; Clark D; Grant AD; Churchyard GJ; Fielding KL
    PLoS One; 2012; 7(8):e43307. PubMed ID: 22905254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of a Novel Algorithm Using Automated Digital Microscopy for Diagnosing Tuberculosis.
    Ismail NA; Omar SV; Lewis JJ; Dowdy DW; Dreyer AW; van der Meulen H; Nconjana G; Clark DA; Churchyard GJ
    Am J Respir Crit Care Med; 2015 Jun; 191(12):1443-9. PubMed ID: 25826383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis in India.
    Little KM; Pai M; Dowdy DW
    PLoS One; 2014; 10(4):e0124525. PubMed ID: 25918999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study.
    Lawn SD; Brooks SV; Kranzer K; Nicol MP; Whitelaw A; Vogt M; Bekker LG; Wood R
    PLoS Med; 2011 Jul; 8(7):e1001067. PubMed ID: 21818180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation.
    Pooran A; Theron G; Zijenah L; Chanda D; Clowes P; Mwenge L; Mutenherwa F; Lecesse P; Metcalfe J; Sohn H; Hoelscher M; Pym A; Peter J; Dowdy D; Dheda K
    Lancet Glob Health; 2019 Jun; 7(6):e798-e807. PubMed ID: 31097281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and cost-effectiveness of Gene Xpert compared to smear microscopy for the diagnosis of pulmonary tuberculosis using real-world data from Arsi zone, Ethiopia.
    Kaso AW; Hailu A
    PLoS One; 2021; 16(10):e0259056. PubMed ID: 34695153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?
    Theron G; Pooran A; Peter J; van Zyl-Smit R; Kumar Mishra H; Meldau R; Calligaro G; Allwood B; Sharma SK; Dawson R; Dheda K
    Eur Respir J; 2012 Jul; 40(1):161-8. PubMed ID: 22075479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.